Rita Assi

Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology

Daniel A. Pollyea, Jessica K. Altman, Rita Assi et al. · Journal of the National Comprehensive Cancer Network · 2023 · 178 citations · Full text

Medicine, Hematology, Oncology +17

Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia

Rita Assi, Hagop M. Kantarjian, Nicholas J. Short et al. · Clinical Lymphoma Myeloma & Leukemia · 2017 · 162 citations

Medicine, Hematology, Oncology +14

Final results of a phase 2, open‐label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome

Rita Assi, Hagop M. Kantarjian, Tapan M. Kadia et al. · Cancer · 2018 · 140 citations · Full text

Medicine, Oncology, Pharmacology +15

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

Farhad Ravandi, Rita Assi, Naval Daver et al. · The Lancet Haematology · 2019 · 138 citations · Full text

Medicine, Hematology, Oncology +16

Impact of the variant allele frequency of <i>ASXL1</i>, <i>DNMT3A</i>, <i>JAK2</i>, <i>TET2</i>, <i>TP53</i>, and <i>NPM1</i> on the outcomes of patients with newly diagnosed acute myeloid leukemia

Koji Sasaki, Rashmi Kanagal‐Shamanna, Guillermo Montalban‐Bravo et al. · Cancer · 2019 · 99 citations

Life Sciences, Genetics, Molecular Genetics +16